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Sodium Bicarbonate Versus Saline
for the Prevention of Contrast-Induced
Nephropathy in Patients With Renal Dysfunction
Undergoing Coronary Angiography or Intervention
Mauro Maioli, MD, Anna Toso, MD, Mario Leoncini, MD, Michela Gallopin, MD,
Delio Tedeschi, MD, Carlo Micheletti, RN, Francesco Bellandi, MD
Prato, Italy
Objectives The purpose of this study was to compare the efficacy of sodium bicarbonate versus isotonic saline in addition
to N-acetylcysteine (NAC) to prevent contrast-induced nephropathy (CIN) in a larger population of patients with
renal dysfunction undergoing coronary angiography or intervention.
Background Contrast-induced nephropathy accounts for more than 10% of hospital-acquired renal failure. Recent studies
suggest that hydration with sodium bicarbonate is more protective than isotonic saline in the prevention of CIN.
Methods The prospective, single center study included 502 patients with estimated creatinine clearance 60 ml/min,
randomized to receive infusion of either saline or sodium bicarbonate before and after iso-osmolar contrast me-
dium administration. All patients received oral NAC 600 mg twice a day. Contrast-induced nephropathy was de-
fined as an absolute increase of serum creatinine 0.5 mg/dl measured within 5 days.
Results Contrast-induced nephropathy occurred in 54 patients (10.8%); 25 (10%) were treated with sodium bicarbonate
and 29 (11.5%) with saline (p  0.60). In patients with CIN, the mean increase in creatinine was not signifi-
cantly different in the 2 study groups (0.9  0.6 mg/dl vs. 0.7  0.2 mg/dl, respectively; p  0.15). Only 2 pa-
tients needed temporary hemofiltration.
Conclusions Hydration with sodium bicarbonate plus NAC before contrast medium exposure is not more effective than hydra-
tion with isotonic saline plus NAC for prophylaxis of CIN in patients with moderate-to-severe renal dysfunction.
(Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy; NCT00606827) (J Am
Coll Cardiol 2008;52:599–604) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.026N
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Pontrast-induced nephropathy (CIN) occurs in up to 15%
f patients with chronic renal impairment undergoing
iagnostic and therapeutic radiographic procedures (1);
.5% to 12% (2) of these patients require dialysis and longer
ospitalization and show persistent worsening of renal
unction, possibly expediting the evolution toward end-
tage renal failure (1,3–5). Moreover, CIN is associated with
n overall higher risk of death (1). The ever-increasing
umber of contrast-medium–based procedures in high-risk
atients makes CIN a relevant possibility in everyday
linical practice.
Several protocols have been tested for the prevention of
IN (6,7), including periprocedural hydration with isotonic
r hypotonic saline (8), antioxidant compounds such as
rom the Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy.M
Manuscript received March 7, 2008; revised manuscript received May 5, 2008,
ccepted May 5, 2008.-acetylcysteine (NAC) (9–12) or ascorbic acid (13), and the
se of low- or iso-osmolar contrast agents (14,15), hemofiltra-
ion (16), or dialysis (17). The results were often disappointing
r inconclusive, and intravenous volume expansion remains to
ate the only measure of undisputed efficacy.
Recently, 3 randomized studies have compared the effects
f sodium bicarbonate versus isotonic saline in humans,
esulting in an impressive reduction of CIN in the sodium
icarbonate group, with an incidence 2% (18–20). The
bjective of the present study was to compare the efficacy of
ydration with sodium bicarbonate versus isotonic saline in
ddition to oral NAC for prophylaxis of CIN in a larger
opulation of patients with chronic kidney dysfunction
ndergoing planned coronary angiography or intervention.
ethods
opulation and study protocol. From January 2005 to
arch 2006, 1,226 patients underwent planned coronary
e
a
t
f
s
r
b
A
d
w
w
l
A
A
o
o
p
m
s
o
p
a
E
p
a
c
c
o
b
a
i
o
b
c
m

s
H
a
600 Maioli et al. JACC Vol. 52, No. 8, 2008
Prevention of Contrast-Induced Nephropathy August 19, 2008:599–604angiographic procedures at our
institution; 502 patients with
pre-angiographic estimated cre-
atinine clearance 60 ml/min
(21) were selected. Figure 1
shows the enrollment criteria and
the trial flow. Randomization
was performed by computerized
open-label assignment in blinded
nvelopes used in a consecutive fashion; 252 patients were
ssigned to saline and 250 to bicarbonate. Patients assigned
o isotonic saline received 1 ml/kg/h 0.9% sodium chloride
or 12 h before and after the procedure (8). Patients in the
odium bicarbonate group (154 mEq/l in dextrose and water)
eceived 3 ml/kg for 1 h before contrast medium, followed
y an infusion of 1 ml/kg/h for 6 h after the procedure (18).
ll patients received 600 mg oral NAC twice a day from the
ay before to the day after the procedure (9).
Echocardiographic evaluation of left ventricular function
as performed in all patients on admission. Hydration rate
as reduced to 0.5 ml/kg/h in both arms for patients with
eft ventricular ejection fraction 40% or New York Heart
ssociation functional class III–IV.
In all cases, iodixanol (Visipaque, GE Healthcare Ltd.,
mersham, United Kingdom), a nonionic, dimeric iso-
smolar contrast medium, was used.
Patients referred
coronary ang
n  = 12
Randomized
creatinine c
<60 ml
Assigned to isotonic saline 
plus oral NAC  n = 252 
Ten days clinical follow up 
and creatinine analysis 
 n = 248 
 
3 patients died 
1 patient with 
acute renal failure  
Figure 1 Flow of Patients
The enrollment criteria and the trial flow. NAC  N-acetylcysteine.
Abbreviations
and Acronyms
CI  confidence interval
CIN  contrast-induced
nephropathy
NAC  N-acetylcysteine
OR  odds ratioSerum creatinine concentration was assessed at the time
f hospital admission and on days 1, 2, 3, 5, and 10 after the
rocedure. A further measurement was performed at 1
onth in all cases of CIN. All tests were performed in a
ingle, hospital-based laboratory with consistent methodol-
gy. Data were recorded in a dedicated database. The
rotocol was approved by the hospital ethics committee and
ll patients gave informed consent.
nd point of the study and definitions. The primary end
oint of the study was the development of CIN, defined as
n absolute increase of at least 0.5 mg/dl over baseline serum
reatinine within 5 days after the administration of the
ontrast medium (5). Additional end points were: 1) devel-
pment of CIN, defined as a relative increase 25% over
aseline serum creatinine within 5 days after contrast agent
dministration; and 2) adverse clinical events, including
n-hospital death, acute pulmonary edema, need for dialysis,
r hemofiltration.
Renal function was categorized according to the stages set
y the National Kidney Foundation (U.S.), with creatinine
learance 90 ml/min considered normal, 60 to 89 ml/min
ildly impaired, 30 to 59 ml/min moderately impaired, and
30 ml/min severely impaired (22). The nephropathy risk
core was calculated as specified by Mehran et al. (2).
igh-contrast load was defined as administered contrast
gent volume 140 ml (23).
ective 
hy 
724 patients excluded for: 
  - creatinine clearance ≥ 60 ml/min n = 691 
  - refusal to participate n = 18 
- administration of contrast medium  
     within the previous 10 days n = 12 
- end stage renal disease n = 3 
02 
e  
Assigned to sodium bicarbonate 
plus oral NAC   n = 250 
Ten days clinical follow up 
and creatinine analysis 
 n = 247 
 
4 patients died 
1 patient with 
acute renal failure   for el
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August 19, 2008:599–604 Prevention of Contrast-Induced Nephropathytatistical analysis. The sample size was calculated by
ssuming a 15% incidence of the study end point in the
sotonic saline hydration group; 500 patients would be
equired (250 per treatment group) to detect a 50% relative
eduction in the incidence of the end point in the sodium
icarbonate group with 90% power at the conventional,
-sided significance level of 5%.
Categorical variables were presented as counts and per-
entages and compared by the chi-square or Fisher exact
est. Continuous variables were compared by the t test for
Baseline Clinical, Biochemical, and Procedural C
Table 1 Baseline Clinical, Biochemical, and
Saline Grou
Age (yrs) 74 (70
Female gender 99 (39
Hypertension 143 (57
Diabetes mellitus 59 (23
NYHA functional class III–IV 18 (7)
Unstable angina 31 (12
Basal serum creatinine (mg/dl) 1.20
Basal creatinine clearance (ml/min) 42
Basal creatinine clearance 30 ml/min 36 (14
Basal serum urea nitrogen (mg/dl) 49
Basal proteinuria (mg/dl) 8
LV ejection fraction (%) 45 (35
LV ejection fraction 40% 78 (31
ACE-I or angiotensin-receptor antagonist 91 (36
Diuretic therapy 82 (33
Aspirin 229 (91
Procedure type
Coronary angiography 104 (41
Elective PCI 148 (59
Mean contrast volume administered (ml) 170 (12
Contrast media volume 140 ml 167 (66
Contrast nephropathy risk score 9 (6–
5 37 (14
6–10 125 (50
11–16 85 (34
17 5 (2)
Normally distributed data are presented as mean value SD, non-nor
categorical data as number (%) of patients. *The values were compa
chi-square or Fisher exact test. ‡The values were compared using the
ACE-I  angiotensin-converting enzyme inhibitor; LV  left ventric
intervention; Saline  isotonic sodium chloride.
aseline and Follow-Up Creatinine Concentrations
Table 2 Baseline and Follow-Up Creatinine Concentrations
Saline
Group
(n  252)
Bicarbonate
Group
(n  250) p Value
Baseline creatinine (mg/dl) 1.20 0.3 1.21 0.3 0.61*
Day 1 post-angiography (mg/dl) 1.15 0.3 1.19 0.4 0.23*
Day 2 post-angiography (mg/dl) 1.20 0.4 1.25 0.4 0.14*
Day 3 post-angiography (mg/dl) 1.22 0.4 1.25 0.5 0.44*
Day 5 post-angiography (mg/dl) 1.22 0.4 1.25 0.5 0.55*
Day 10 post-angiography (mg/dl) 1.20 0.3 1.22 0.4 0.67*
Peak creatinine
post-angiography (mg/dl)
1.34 0.4 1.37 0.5 0.59*The values were compared using the unpaired t test.ormally distributed values; otherwise, the Mann-Whitney
test was used. Multivariate logistic regression analysis was
erformed using all potentially relevant variables to identify
10.0
20.6
15.2 15.1
10.0
11.5
0
5
10
15
20
%
NS
NS
NS Isotonic Saline
Sodium Bicarbonate
Figure 2 End Points in the Study Groups
Incidence of primary end point (left) (absolute increase of creatinine 0.5
mg/dl over baseline value within 5 days after the administration of the radio-
graphic contrast medium). Incidence of secondary end point: relative increase
of creatinine 25% over baseline value within 5 days (middle) and within 2
cteristics of Study Patients
edural Characteristics of Study Patients
252) Bicarbonate Group (n  250) p Value
74 (67–79) 0.52*
107 (43) 0.42†
147 (59) 0.64†
62 (25) 0.71†
19 (8) 0.85†
37 (15) 0.41†
1.21 0.3 0.61‡
43 11 0.67‡
39 (16) 0.68†
50 20 0.77‡
10 31 0.68‡
48 (37–55) 0.41*
65 (26) 0.27†
106 (42) 0.15†
76 (30) 0.61†
225 (90) 0.85†
0.91†
102 (41)
148 (59)
0) 160 (120–220) 0.80*
171 (69) 0.56†
9 (6–11) 0.69*
48 (19) 0.34†
113 (45)
80 (32)
9 (4)
istributed data are expressed as median with interquartile range, and
ng the Mann-Whitney U test. †The values were compared using the
ed t test.
YHA  New York Heart Association; PCI  percutaneous coronarydays (right) after contrast agent administration. NS  no significant difference.hara
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-tailed and statistical significance was defined as p  0.05.
ll analyses were performed with SPSS statistical software,
ersion 13.0 (SPSS Inc., Chicago, Illinois).
esults
linical characteristics. No significant differences in base-
ine clinical, biochemical, and procedural characteristics
ere found between the 2 groups (Table 1). In particular,
igher-risk patients presenting with diabetes, worse baseline
enal function, left ventricular dysfunction, or advanced
eart failure were evenly distributed. Overall, 15% of pa-
ients had severe renal impairment with basal creatinine
learance 30 ml/min.
ontrast-induced nephrotoxicity. Mean creatinine values
n the 2 groups are shown in Table 2. In both groups,
reatinine significantly increased after contrast medium
baseline vs. peak, p  0.001). The mean absolute increase
as not significantly different in the 2 groups (0.14  0.3
g/dl saline vs. 0.15  0.4 mg/dl bicarbonate, p  0.78).
urthermore, the mean creatinine concentration measured
n day 10 was similar in the 2 groups and was not
ignificantly different from the baseline value in each group.
The primary end point of CIN occurred in 54 patients
10.8%): 29 (11.5%) in the saline and 25 (10%) in the
odium bicarbonate group (p  0.60) (Fig. 2, left). No
ignificant difference was observed between the 2 groups,
ven when CIN was defined as 25% relative increase in
aseline serum creatinine (20.6% saline vs. 15.2% bicarbon-
te; p 0.13) (Fig. 2, middle). Furthermore, by limiting the
nalysis to within 48 h, no significant trend favoring the
icarbonate group was observed (10% vs. 15.1%, p  0.09)
Fig. 2, right).
Table 3 shows creatinine values in patients with CIN; no
ignificant differences were found between the 2 groups. At
month, creatinine values remained significantly higher
han baseline in patients who developed CIN (1.6  0.5
g/dl vs. 1.4  0.3 mg/dl, respectively; p  0.001) with a
aseline and Follow-Up Creatinineonce tr tions in Patients W th CIN
Table 3 Baseline and Follow-Up CreatinineConcentrations in Patients With CIN
Saline
Group
(n  29)
Bicarbonate
Group
(n  25) p Value
Baseline creatinine (mg/dl) 1.38 0.3 1.42 0.4 0.65*
Day 1 post-angiography (mg/dl) 1.60 0.4 1.79 0.4 0.10*
Day 2 post-angiography (mg/dl) 1.83 0.5 2.08 0.5 0.10*
Day 3 post-angiography (mg/dl) 1.87 0.4 2.04 0.7 0.31*
Day 5 post-angiography (mg/dl) 1.86 0.5 1.95 0.9 0.64*
Day 10 post-angiography (mg/dl) 1.71 0.4 1.69 0.5 0.90*
1 month post-angiography (mg/dl) 1.62 0.4 1.61 0.6 0.97*
Peak creatinine post-angiography
(mg/dl)
2.11 0.4 2.36 0.7 0.13*
Mean increase in serum creatinine
(mg/dl)
0.73 0.2 0.94 0.7 0.15*g
The values were compared using the unpaired t test.
CIN  contrast-induced nephropathy.% reduction in creatinine clearance (p  0.014), without
ignificant differences between the 2 groups.
As expected, the incidence of CIN significantly increased
n high-risk patients: 5% in low and moderate nephropathy
isk scores versus 21% in high and very high risk scores (p
.001) and 16.5% in diabetics versus 8.4% in nondiabetics
p 0.01). Table 4 shows the incidence of CIN in high-risk
atients.
linical events in CIN patients. There were 7 (1.4%)
eaths in the entire series of 502 patients: 5 patients died
rom acute cardiac failure, 1 from infective multiorgan
ailure, and 1 from sudden death. Of the 7 patients who
ied, 3 were in the saline group (1.2%) and 4 in the
icarbonate group (1.6%; p  0.99). Of these patients, 6
eveloped CIN (mortality rate 11.1% in CIN patients vs.
.2% in non-CIN patients; p 0.001); only 2 patients (1 in
ach group) were treated with temporary hemofiltration and
one required long-term dialysis.
isk factor analysis. Forward stepwise logistic regression
nalysis revealed diabetes mellitus (odds ratio [OR]: 2.3,
5% confidence interval [CI]: 1.2 to 4.4; p  0.016), left
entricular ejection fraction (OR: 1.05, 95% CI: 1.03 to
.08; p  0.001, for every 1-point reduction), and
reatinine clearance (OR: 1.07, 95% CI: 1.04 to 1.10; p
.001, for every 1-ml/min reduction) as independent
redictors of CIN in both the saline and the bicarbonate
roups.
iscussion
o our knowledge, this is the largest randomized study
omparing isotonic saline and sodium bicarbonate in the
rophylaxis of CIN. The results suggest that, in patients
ith moderate-to-severe renal dysfunction, the occurrence
f CIN is not significantly different in patients receiving
sotonic saline compared with sodium bicarbonate for
eriprocedural hydration, in addition to oral NAC. More-
ver, there was no difference between the 2 treatments also
n patients with pre-existing severe renal impairment, dia-
etes, or high nephropathy risk score.
Alterations in renal hemodynamics and direct tubular
oxicity are considered primary factors in the pathogenesis
f CIN (4) that lead to a decrease in renal blood flow and
ncidence of CIN Among Patientst High Risk for Development of CIN
Table 4 Incidence of CIN Among Patientsat High Risk for Development of CIN
Saline
Group
Bicarbonate
Group p Value
High and very high contrast
nephropathy risk score, 11
21/90 (23%) 16/89 (18%) 0.38*
Creatinine clearance 30 ml/min 10/36 (28%) 10/39 (26%) 0.83*
Diabetes mellitus 12/59 (20%) 8/62 (13%) 0.27*
Percutaneous coronary intervention 18/148 (12%) 16/148 (11%) 0.71*
Contrast media volume 140 ml 10/85 (12%) 7/77 (9%) 0.62*
The values were compared using the chi-square or Fisher exact test.
CIN  contrast-induced nephropathy.lomerular filtration rate. Compromise of renal function
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August 19, 2008:599–604 Prevention of Contrast-Induced Nephropathyncreases mortality, length of hospitalization and medical
osts, and accelerates end-stage renal disease (3). The results
f the present study confirm that CIN is not a benign
ondition, because it is associated with a significantly higher
n-hospital mortality and a significant reduction in the
stimated creatinine clearance at 1 month.
We used a single iso-osmolar contrast medium for the
ntire study to avoid bias and problems of varying responses
o different media.
The administration of fluids is the cornerstone treatment
o reduce the risk of CIN (6,7). Although the optimal
ydration strategy is uncertain, available data support a
egimen of 0.9% saline at 1 ml/kg/h intravenously for 12 h
efore administration of the contrast medium and continu-
ng for up to 12 h after (7).
The prophylactic oral administration of the antioxidant
AC to patients with renal impairment has been investi-
ated on the assumption that reactive oxygen species are
nvolved in CIN. Although some studies suggest that NAC
ay reduce the incidence of CIN (10), a review of clinical
tudies by Fishbane et al. (11) has demonstrated mixed
esults. Therefore, use of NAC, although not recommended
or all patients, may be appropriate for patients at very high
isk of CIN (24).
If oxygen radicals were involved in the pathogenesis of
IN, hydration with an alkaline solution, such as sodium
icarbonate, might further reduce subsequent renal dam-
ge. On this basis, 3 recent studies comparing the results
f saline and bicarbonate administration suggest a strik-
ng superiority of bicarbonate over saline (18 –20). Hy-
ration with bicarbonate showed a very low incidence of
IN (1.7% to 1.9%), notwithstanding the pre-existing
nding of severe renal dysfunction (18,19). The study by
erten et al. (18) was terminated early because of a
ower-than-expected rate of events in the bicarbonate
roup, but the timing of the interim analysis and the rules
or early termination were not specified in advance (7).
oreover, the hydration protocol with saline was uncon-
entional, which does not allow direct comparisons with
ther studies. In the REMEDIAL (Renal Insufficiency
ollowing Contrast Media Administration Trial) trial by
riguori et al. (19), the occurrence of CIN was assessed
t 48 h, and this could account for an underestimation of
IN. In fact, creatinine usually peaks 4 to 5 days after
ontrast agent administration (13,25–27). If we had
imited the assessment to the first 48 h, we would have
issed about 30% of CIN-positive patients (18/54 pa-
ients). Still, in the REMEDIAL trial, the incidence of
IN was unexpectedly low (1.9%) in the bicarbonate plus
AC group, significantly lower than in the other treat-
ent arms. In the RENO study by Recio-Mayoral et al.
20), which enrolled patients with acute coronary syn-
rome who were undergoing emergency percutaneous
oronary intervention, a very low CIN incidence was
onfirmed (1.8%) with bicarbonate.It is difficult to comment on the marked difference in
he results between these previous studies and the present
ne. Possible explanations include the population size,
he extension of creatinine monitoring up to 5 days, and
he planned nature of the procedure. However, no
efinitive explanation can be found. Our data are consis-
ent with the retrospective analysis performed by Schmidt
t al. (28) that did not show significant differences
etween bicarbonate and saline. In any case, the relevant
ifferences in incidence among studies reveal the need for
 uniform definition of CIN to be used in clinical practice
s well as in research.
tudy limitations. The main limitation of our trial was
ts single center basis. Furthermore, most patients had
oderate renal insufficiency and only 15% showed creat-
nine clearance 30 ml/min. We did not study the effects
f bicarbonate on the urine or arterial pH and neither we
or other researchers evaluated the cystatin C levels
nown to be the most reliable marker of kidney damage,
lthough these levels are influenced by other factors as
ell.
onclusions
ydration with sodium bicarbonate plus oral NAC
efore contrast medium exposure is not more effective
han hydration with isotonic sodium chloride plus oral
AC for prophylaxis of CIN in patients with moderate
enal dysfunction. Sodium bicarbonate requires only 1 h
f pre-treatment and may represent an option in patients
cheduled for urgent agent injection or for outpatient
rocedures.
eprint requests and correspondence: Dr. Mauro Maioli, Via
egli Arcipressi 3, 50143, Florence, Italy. E-mail: mauro.maioli@
astwebnet.it.
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